• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cyclacel Pharmaceuti (NQ: CYCC )

    0.6269 -0.0221 (-3.41%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 216,617
    Open 0.6320
    Bid (Size) 0.6230 (1)
    Ask (Size) 0.6239 (2)
    Prev. Close 0.6490
    Today's Range 0.6000 - 0.6364
    52wk Range 0.6000 - 10.12
    Shares Outstanding 1,974,204
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule
    From Cyclacel
    Via GlobeNewswire

    Performance

    YTD
    -76.34%
    -76.34%
    1 Month
    -31.85%
    -31.85%
    3 Month
    -57.06%
    -57.06%
    6 Month
    -69.71%
    -69.71%
    1 Year
    -92.81%
    -92.81%

    More News

    Read More
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
    From Cyclacel
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter
    From Cyclacel
    Via GlobeNewswire
    Why Zhibao Technology Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    CYCC Stock Earnings: Cyclacel Pharmaceuticals Beats EPS, Misses Revenue for Q2 2024
    Via InvestorPlace
    Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
    From Cyclacel
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer
    From Cyclacel
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    CYCC Stock Earnings: Cyclacel Pharmaceuticals Beats EPS for Q1 2024
    Via InvestorPlace
    Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
    From Cyclacel
    Via GlobeNewswire
    Why Akoustis Technologies Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.